Harbour BioMed appoints Adam Zong president

  • Harbour BioMed appointed Adam Zong as president on April 16, 2026.
  • Zong will be based in Shanghai, reporting to founder, chairman, CEO Jingsong Wang.
  • Role includes strengthening internal pipeline, steering portfolio strategy, leading asset strategy, partnership initiatives.
  • He previously served as principal consultant at Arc Nouvel Clinical Development Consulting.
  • Zong was founding CEO of Hengrui Therapeutics U.S., with earlier senior roles at Merck, Bristol Myers Squibb, Schering-Plough, Pfizer.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. HBM Holdings Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202604160320PR_NEWS_USPR_____CN36121) on April 16, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.